These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7199651)

  • 1. Alternate day levodopa therapy in parkinsonism.
    Koller WC
    Neurology; 1982 Mar; 32(3):324-6. PubMed ID: 7199651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent levodopa therapy in parkinsonism.
    Koller WC
    Adv Neurol; 1983; 37():45-50. PubMed ID: 6407286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
    Papavasiliou PS; McDowell FH; Wang YY; Rosal V; Miller ST
    Neurology; 1979 Feb; 29(2):194-200. PubMed ID: 571063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
    Papavasiliou PS; Cotzias GC; Rosal VL; Miller ST
    Arch Neurol; 1978 Dec; 35(12):787-91. PubMed ID: 363104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
    Melamed E; Bitton V; Zelig O
    Neurology; 1986 Jan; 36(1):100-3. PubMed ID: 3941762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
    Vilhena Rde O; Pontes FL; Marson BM; Ribeiro RP; de Carvalho KA; Cardoso MA; Pontarolo R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():41-9. PubMed ID: 25063927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
    Amano K; Takakura K
    Stereotact Funct Neurosurg; 1997; 69(1-4 Pt 2):5-18. PubMed ID: 9711730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of L-dopa in patients with Parkinson's disease.
    Mena MA; Muradas V; Bazan E; Reiriz J; de Yebenes JG
    Adv Neurol; 1987; 45():481-6. PubMed ID: 2950730
    [No Abstract]   [Full Text] [Related]  

  • 13. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease.
    Nyholm D; Johansson A; Aquilonius SM; Hellquist E; Lennernäs H; Askmark H
    Clin Neuropharmacol; 2012; 35(1):6-14. PubMed ID: 22094648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
    Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Woitalla D
    Mov Disord; 2006 Mar; 21(3):332-6. PubMed ID: 16211593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 17. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 18. Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness.
    Hale MS; Bellizzi J
    J Nerv Ment Dis; 1980 May; 168(5):312-4. PubMed ID: 7365497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients who fail to respond to levodopa therapy.
    Duvoisin RC
    Clin Neuropharmacol; 1982; 5 Suppl 1():S13-8. PubMed ID: 7116342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.